Neurohormonal Parameters in Hypertrophic Cardiomyopathies
NCT ID: NCT01729702
Last Updated: 2014-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
131 participants
INTERVENTIONAL
2009-04-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Etiological DiagnOsis of caRdiac Diseases Based on echoCardiograpHIc Images and Clinical Data.
NCT05942729
Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies
NCT04129905
Comparison of Ultrafast Echo With Echotracking
NCT01743352
Exercise Oxygen Kinetic and Cardiac Output in Hypertrophic Cardiomyopathy
NCT05754489
French Hypertrophic Cardiomyopathy Observatory
NCT01091480
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
single group - consecutive patients
blood sample collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sample collection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive, with studies of exercise peak oxygen consumption and cardiac MRI with gadolinium late-enhancement
* Informed consent
* Patient with a social insurance Patient at rest
* \- Age 18 to 75 years
* Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive
* Informed consent
* Patient with a social insurance
Exclusion Criteria
* Permanent atrial fibrillation
* Complete BBB on the ECG
* LVEF \< 35 %
* Previous septal ablation (surgical or percutaneous)
* Simultaneous participation to another biomedical research
If exercise needed:
* contraindication to exercise : hemodynamic instability, uncontrolled high blood pressure (\>220/120 mmHg), severe aortic stenosis
* Inability to exercise (muscular, pulmonary, elderly patient)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
French Cardiology Society
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Albert Hagège, MD-PhD
Role: STUDY_CHAIR
HEGP - Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Européen Georges Pompidou
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.